The independent source for health policy research, polling, and news.
301 - 320 of 1,309 Results
“What happens in Texas doesn't stay in Texas,” warns an abortion rights advocate bracing for a district judge’s ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics aren’t always the lowest-priced deal.
A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDA’s 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s chief Washington correspondent, Julie Rovner, to discuss these issues and more.
Twitter has been a hotbed for the burgeoning insulin access movement and activism surrounding other medical conditions. For people with diabetes, the platform has helped propel concern about insulin prices into policy. Can it continue to win with hashtags?
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
Insurers, employers, and taxpayers will all be affected as drug manufacturers move these products to the commercial market.
President Joe Biden’s 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
The nation’s largest Medicaid insurer denies wrongdoing after the California attorney general’s office investigated it for inflating prescription drug costs.
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of “Medicare for All” maps out his strategy for negotiating with Republicans — and Big Pharma.
The online women’s pharmacy agreed to pay $15 million to the state Department of Justice and $3.3 million to the Department of Insurance over claims it overbilled Medi-Cal.
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine.
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren’t necessarily investing in centers with the best treatment standards, and they often cut extra services.
In Part II of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also, for extra credit, the panelists recommend their most memorable reproductive health stories from the last year.
Supporters of a proposed law say it would fill a health provider gap in rural areas, while doctors worry it will give pharmacists power outside the scope of their education.
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
© 2026 KFF